Heparanase – Drugs In Development, 2021

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) pipeline Target constitutes close to 15 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report Heparanase – Drugs In Development, 2021, outlays comprehensive information on the Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) – Heparanase is an endoglycosidase which cleaves heparan sulfate (HS) and hence participates in degradation and remodeling of the extracellular matrix (ECM). Heparanase is preferentially expressed in human tumors and its over-expression in tumor cells. The enzyme also releases angiogenic factors from the ECM and thereby induces an angiogenic response. Heparanase exhibits also non-enzymatic activities, independent of its involvement in ECM degradation. Among these, are the enhancement of Akt signaling, stimulation of PI3K- and p38-dependent endothelial cell migration, and up regulation of VEGF, all contributing to its potent pro-angiogenic activity. Inhibiting the enzyme is beneficial in treatment of cancer.

The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4 and 8 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Ophthalmology, Hematological Disorders and Immunology which include indications Coronavirus Disease 2019 (COVID-19), Pancreatic Cancer, Retinopathy, Blood Coagulation, Breast Cancer, Dengue Fever, Dry (Atrophic) Macular Degeneration, Head And Neck Cancer, Inflammation, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Refractory Multiple Myeloma, Solid Tumor, Triple-Negative Breast Cancer (TNBC) and Wet (Neovascular / Exudative) Macular Degeneration.

Furthermore, this report also reviews key players involved in Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166)

– The report reviews Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics and enlists all their major and minor projects

– The report assesses Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

B-Side Pharma Ltd

Beta Therapeutics Pty Ltd

CarboMimetics

HepaRx Ltd

Johnson & Johnson

Leadiant Biosciences Inc

Shenzhen Hepalink Pharmaceutical Group Co Ltd

Zucero Therapeutics Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC

3.2.1.166) - Overview

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC

3.2.1.166) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC

3.2.1.166) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC

3.2.1.166) - Companies Involved in Therapeutics Development

B-Side Pharma Ltd

Beta Therapeutics Pty Ltd

CarboMimetics

HepaRx Ltd

Johnson & Johnson

Leadiant Biosciences Inc

Shenzhen Hepalink Pharmaceutical Group Co Ltd

Zucero Therapeutics Ltd

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC

3.2.1.166) - Drug Profiles

BT-2180 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CM-30119 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

H-1710 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JVB-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JVB-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JVB-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JVB-14 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

necuparanib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pixatimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Polysaccharides to Inhibit Heparanase for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

roneparstat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Heparanase for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Heparanase for Inflammatory Diseases and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Heparanase for Type 1 and Type 2 Diabetes and Age Related Macular Degeneration - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit HPSE and VEGF for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC

3.2.1.166) - Dormant Products

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC

3.2.1.166) - Discontinued Products

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC

3.2.1.166) - Product Development Milestones

Featured News & Press Releases

Aug 04, 2016: Momenta Discontinues Further Accrual of its Phase 2 Trial of Necuparanib in Patients with Pancreatic Cancer Following Planned Interim Futility Analysis

Jun 04, 2016: Momenta Pharmaceuticals Announces Presentation of Final Data from Phase 1 Trial of Necuparanib in Patients with Pancreatic Cancer at ASCO

May 19, 2016: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib at the 2016 ASCO Annual Meeting

Dec 21, 2015: Momenta Resumes Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study

Nov 13, 2015: Momenta Announces Temporary Pause of Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study

Jun 01, 2015: Momenta Pharmaceuticals to Present New Data From Phase 1 Trial of Necuparanib in Patients With Pancreatic Cancer

May 18, 2015: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib (M402) at the 2015 ASCO Annual Meeting

Dec 01, 2014: Momenta Pharmaceuticals' Necuparanib Receives Fast Track Designation From the FDA for the Treatment of Patients With Metastatic Pancreatic Cancer

Oct 09, 2014: Momenta Pharmaceuticals Announces Top-Line Part A Results From Phase 1/2 Trial of Necuparanib in Patients With Pancreatic Cancer

Oct 09, 2014: Momenta Pharmaceuticals Announces Top-Line Part A Results From Phase 1/2 Trial of Necuparanib in Patients With Pancreatic Cancer

Jul 21, 2014: European Patent Office Intention to Grant ‘Sulfated Oligosaccharide Derivatives’ Patent

Jun 05, 2014: Momenta Pharmaceuticals Receives Orphan Drug Designation for Necuparanib (Formerly M402) in Pancreatic Cancer

Oct 29, 2013: PG545 Phase 1 Cancer Trial Update

Jul 09, 2013: PG545 Pre-Clinical Data in Experimental Pancreatic Cancer Models Published in Molecular Cancer Therapeutics

May 13, 2013: Sigma-Tau announces Phase I study with new anti-cancer heparanase inhibitor SST0001

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indication, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Number of Products under Investigation by Universities/Institutes, 2021

Products under Investigation by Universities/Institutes, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by B-Side Pharma Ltd, 2021

Pipeline by Beta Therapeutics Pty Ltd, 2021

Pipeline by CarboMimetics, 2021

Pipeline by HepaRx Ltd, 2021

Pipeline by Johnson & Johnson, 2021

Pipeline by Leadiant Biosciences Inc, 2021

Pipeline by Shenzhen Hepalink Pharmaceutical Group Co Ltd, 2021

Pipeline by Zucero Therapeutics Ltd, 2021

Dormant Products, 2021

Dormant Products, 2021 (Contd..1)

Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports